Parameter
| Biomarker | PTEN | Full name | Phosphatase and tensin homolog | Molecular Type | Nucleic acid（DNA） |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis |
| Disease | Endometrial Cancer | Disease Subtypes | / | ||
| Organ | Endometrium | Test Sample / Technology Platform | Whole blood / Tumor tissue (NGS, Sanger sequencing) | ||
| Pathobiological Mechanisms | Tumor suppressor genes, when mutated, cause the protein to lose its function and fail to inhibit the PI3K/AKT pathway, thereby promoting tumor formation and invasion. | ||||
| Clinical Availability Status | Clinical validation (classification / prognosis): Approximately 30% - 40% of endometrial cancer cases have mutations, and patients with mutated genes have a relatively better prognosis. | ||||
| Notes and Dynamics | It is a core driver mutation of endometrioid carcinoma, which can serve as a screening marker for targeted PI3K pathway therapy. | ||||